IXICO PlC (AIM: IXI) Chief Commercial Officer, Lammert Albers joined Steve Darling from Proactive with news the company is to provide neuroimaging services that will support a phase Ib/II clinical trial for Huntington’s disease.
Albers telling Proactive "these services will enable clients to measure the impact of the trialled drugs with greater confidence and potentially unlock new insights into disease progression and drug development.”
